← USPTO Patent Grants

Dosage regime

Grant US12576050B2 Kind: B2 Mar 17, 2026

Assignee

NOVABIOTICS LIMITED

Inventors

Deborah O'Neil

Abstract

The present disclosure relates to use of cysteamine, formulations comprising cysteamine and pharmaceutically acceptable salts of cysteamine in the treatment of cystic fibrosis and conditions associated with cystic fibrosis.

CPC Classifications

A61K 31/145 A61P 11/00 A61P 11/12

Filing Date

2019-10-17

Application No.

17286282

Claims

11